Levetiracetam in acute manic episode of bipolar disorder

Investigating the efficacy of Levetiracetam adjunct to Olanzapine for acute manic episode of bipolar disorder, a Double-blind placebo controlled randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211118053093N6

Enrollment

Registered

2023-07-31

Start date

2023-08-23

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder type one. Manic episode

Interventions

Intervention 1: Control group: In the control group, olanzapine starts with a dose of 5 mg per day and reaches a maximum of 20 mg. Lithium also starts with a dose of 300 mg and reaches a maximum of 90

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: BID diagnosis based on DSM-V criteria Y-BOCS score equal or more than 20

Exclusion criteria

Exclusion criteria: Drug abuse Pregnancy Medical problems

Design outcomes

Primary

Measure	Time frame
Young mania rating scale. Timepoint: Week 0, 4, 8 and 16. Method of measurement: Young mania rating scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Razeghian Jahromi

Shiraz University of Medical Sciences

leilarazeghian1366@gmail.com+98 71 3260 5701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026